Treatment of Patients With Chronic Hepatitis C With PegIntron as Monotherapy or in Combination With Ribavirin (Study P04437)(COMPLETED) (ADEQUATION)

Merck Sharp & Dohme (MSD)

Status: Completed

Conditions: Hepatitis C, Chronic; Hepacivirus

Treatments: Drug: Ribavirin (SCH 18908); Biological: Peginterferon alfa-2b (SCH 54031)

Study type: Observational

Funder types: Industry

Identifiers

NCT00705666

P04437

Details and patient eligibility

About

In February 2002, a French Consensus Conference on the management of patients with chronic hepatitis C in France was organized. The jury issued several recommendations on pegylated alpha interferon/ribavirin treatment strategy. Three years after these recommendations, it is of interest to understand the evolution of hepatitis C management in France in real clinical practice. This observational study will permit the identification of patients who are treated and will provide information on the use of PegIntron/ Ribavirin.

Full description

To assure a good representation of participants treated for hepatitis C, participants who meet the inclusion criteria will be enrolled on a consecutive basis.

Enrollment: 789 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult participants starting a treatment with PegIntron for the treatment of chronic hepatitis C.

Exclusion criteria

• Concomitant participation in a clinical trial for the treatment of hepatitis C.

Trial design

789 participants in 1 patient group

PegIntron as monotherapy or in combination with Ribavirin.

Description:

Adult participants with chronic hepatitis C treated with PegIntron as monotherapy or in combination with ribavirin.

Treatment:

Drug: Ribavirin (SCH 18908)

Biological: Peginterferon alfa-2b (SCH 54031)